DNA Genotek

Belkins
In 2010, DNA Genotek launched Performagene™, a non-invasive method for collecting DNA from livestock and companion animals. To date, the company released three new products: ORAcollect®, prepIT® and OMNIgene®•DISCOVER.

Related News

OUTSOURCING BIOLOGY CRO AND PRECLINICAL RESEARCH STUDIES DURING COVID19 PANDEMIC

PR Newswire | May 15, 2020

news image

While the COVID-19 pandemic continues to evolve, many Cancer Research Institutions and Pharma/Biotech companies are considering how to restart the biomedical research and drug development programs. This may include thinking through meeting the timeline, risk of mitigation actions, and possible program reprioritizations as components of the strategy to return to normal operations. Our preclinical services allow scientists to discover new innovative therapies effective in serious diseases without ...

Read More

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

news image

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

news image

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

Labiotech | January 15, 2020

news image

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More

PR Newswire | May 15, 2020

news image

OUTSOURCING BIOLOGY CRO AND PRECLINICAL RESEARCH STUDIES DURING COVID19 PANDEMIC

While the COVID-19 pandemic continues to evolve, many Cancer Research Institutions and Pharma/Biotech companies are considering how to restart the biomedical research and drug development programs. This may include thinking through meeting the timeline, risk of mitigation actions, and possible program reprioritizations as components of the strategy to return to normal operations. Our preclinical services allow scientists to discover new innovative therapies effective in serious diseases without ...

Read More

BioSpace | April 16, 2020

news image

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

Biomica | October 13, 2020

news image

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More

Labiotech | January 15, 2020

news image

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More